Tubulin polymerization-IN-88

Tubulin polymerization-IN-88 是一种微管蛋白 (tubulin) 抑制剂,可通过阻断微管蛋白聚合引发微管去稳定化和有丝分裂纺锤体破坏,诱导癌细胞发生 G2/M 期阻滞和细胞凋亡 (apoptosis),抑制癌细胞迁移和癌症干细胞的自我更新,对癌细胞具有体外抗增殖活性且相较于正常细胞具有选择性,并具有体内抗癌活性且无明显毒性,可用于胶质母细胞瘤、肺癌、子宫内膜癌、卵巢癌、白血病的研究。
Tubulin polymerization-IN-88
产品编号: MS-G88195 分子式: C30H39N3O3S 分子量: 521.71
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Tubulin polymerization-IN-88 是一种微管蛋白 (tubulin) 抑制剂,可通过阻断微管蛋白聚合引发微管去稳定化和有丝分裂纺锤体破坏,诱导癌细胞发生 G2/M 期阻滞和细胞凋亡 (apoptosis),抑制癌细胞迁移和癌症干细胞的自我更新,对癌细胞具有体外抗增殖活性且相较于正常细胞具有选择性,并具有体内抗癌活性且无明显毒性,可用于胶质母细胞瘤、肺癌、子宫内膜癌、卵巢癌、白血病的研究。

生物实验数据

生物活性 Tubulin polymerization-IN-88 is a tubulin inhibitor that blocks tubulin polymerization to trigger microtubule destabilization and mitotic spindle disruption, induces G2/M phase arrest and apoptosis in cancer cells, inhibits cancer cell migration and cancer stem cell self-renewal, exhibits in vitro antiproliferative activity against cancer cells with selectivity over normal cells, and possesses in vivo anticancer activity without obvious toxicity, making it applicable for research on glioblastoma, lung cancer, endometrial cancer, ovarian cancer, and leukemia.
IC50 & Target

Bcl-xL

 

体外研究
(In Vitro)

Tubulin polymerization-IN-88 (compound 9b) (作用时间 72 h) 可强效抑制胶质母细胞瘤 (U87 MG、A172、U118 MG)、肺癌 (A549)、卵巢癌 (SKOV3)、白血病 (K562、HL60) 等多种癌细胞系的增殖,其 IC50 值范围为 0.27 至 12.45 μM,同时对正常 293T 细胞无毒性。
Tubulin polymerization-IN-88 (1-30 μM;作用 24 h) 可在浓度 ≥3 μM 时诱导 U118 MG 细胞发生剂量依赖性凋亡,并下调 Bcl-XL 的表达。
Tubulin polymerization-IN-88 (0.1-1 μM;24-72 h) 通过划痕伤口愈合实验和 Transwell 实验,以浓度和时间依赖的方式强效抑制 U118 MG 细胞的迁移。
Tubulin polymerization-IN-88 (1-30 μM;处理 3 天) 可通过降低神经球形成能力并下调 CD133 和 SOX2 的表达,有效抑制 U118 MG 癌症干细胞的自我更新。
Tubulin polymerization-IN-88 (1-30 μM;作用 24 h) 可通过下调 Cyclin B1 和 CDK1 诱导 U118 MG 细胞发生 G2/M 期阻滞。
Tubulin polymerization-IN-88 (1-30 μM;作用 24 h) 可破坏 U118 MG 细胞中的微管蛋白聚合及纺锤体微管组装,进而降低 α/β-微管蛋白的表达。

Cell Viability Assay

Cell Line: U87 MG, A172, U118 MG, A549, ISK, SKOV3, U251, K562, HL60, 293T
Concentration: varied for IC₅₀ determination
Incubation Time: 72 h
Result: Inhibited proliferation of U87 MG cells with an IC50 of 0.27 μM; inhibited proliferation of A172 cells with an IC50 of 1.22 μM; inhibited proliferation of U118 MG cells with an IC50 of 0.88 μM; inhibited proliferation of A549 cells with an IC50 of 0.33 μM; inhibited proliferation of ISK cells with an IC50 of 12.45 μM; inhibited proliferation of SKOV3 cells with an IC50 of 0.47 μM; inhibited proliferation of U251 cells with an IC50 of 1.29 μM; inhibited proliferation of K562 cells with an IC50 of 0.73 μM; inhibited proliferation of HL60 cells with an IC50 of 2.02 μM; showed negligible toxicity to 293T cells with an IC50 >100 μM.

Apoptosis Analysis

Cell Line: U118 MG
Concentration: 1, 3, 10, 30 μM
Incubation Time: 24 h
Result: Induced dose-dependent increase in total apoptotic cells, with statistical significance at and above 3 μM; downregulated anti-apoptotic protein Bcl-XL in a concentration-dependent manner.

Cell Migration Assay

Cell Line: U118 MG
Concentration: 0.1, 0.3, 1 μM
Incubation Time: 24, 48, 72 h (scratch assay); 24 h (transwell assay)
Result: Inhibited scratch wound closure in a concentration- and time-dependent manner (significant inhibition at 72 h); dose-dependently reduced transwell migration.

Cell Cycle Analysis

Cell Line: U118 MG
Concentration: 1, 3, 10, 30 μM
Incubation Time: 24 h
Result: Induced G2/M phase arrest at low concentrations (1-10 μM); dose-dependently reduced expression of cell cycle regulators Cyclin B1 and CDK1.

Western Blot Analysis

Cell Line: U118 MG
Concentration: 1, 3, 10, 30 μM
Incubation Time: 24 h
Result: Significantly reduced α/β-tubulin protein
expression in U118 MG cells.
体内研究
(In Vivo)

Tubulin polymerization-IN-88 (compound 9b) (2.5-20 mg/kg; i.p.; daily; 28 days) 在体内表现出强效的剂量依赖性抗胶质母细胞瘤活性,肿瘤重量生长抑制率 (TGI) 为 49.7-49.8%,且具有可接受的安全性特征。

Animal Model: BALB/c nude (male, 6-7 weeks old, 16-19 g, U118 MG xenograft model)
Dosage: 2.5, 8, 20 mg/kg
Administration: i.p.; daily; 28 days
Result: Suppressed tumor growth dose-dependently; induced 49.7% tumor weight growth inhibition (TGI) at 8 mg/kg, and 49.8% TGI at 20 mg/kg (both statistically significant vs control); caused no significant body weight loss or overt toxicity.

化学信息

分子量 521.71
分子式 C30H39N3O3S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础